|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2014
|
|
gptkbp:ATCCode
|
L01XE31
|
|
gptkbp:bioavailability
|
4.7%
|
|
gptkbp:brand
|
gptkb:Ofev
gptkb:Vargatef
|
|
gptkbp:CASNumber
|
656247-17-5
|
|
gptkbp:chemicalFormula
|
C31H33N5O4
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to nintedanib
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:eliminationHalfLife
|
9.5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nintedanib
|
|
gptkbp:KEGGID
|
D09916
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits multiple receptor tyrosine kinases
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
539.6 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108508
11612396
DB09079
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
elevated liver enzymes
|
|
gptkbp:UNII
|
8LJ08WK8A3
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
idiopathic pulmonary fibrosis
systemic sclerosis-associated interstitial lung disease
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|